# MYCN

## Overview
The MYCN gene encodes the MYCN proto-oncogene, a basic helix-loop-helix (bHLH) transcription factor that plays a pivotal role in cellular processes such as proliferation, differentiation, and apoptosis. As a member of the MYC family of proto-oncogenes, MYCN is characterized by its ability to form heterodimers with the MYC-associated protein X (MAX), facilitating its function in transcriptional regulation (RuizPérez2017The). The protein is particularly significant in the development of the nervous system and is implicated in various cancers, most notably neuroblastoma, where its amplification is associated with poor prognosis and aggressive tumor behavior (Bhavsar2023Metastasis; Braoudaki2021MYCN). Despite its critical role in oncogenesis, MYCN is considered challenging to target therapeutically due to its intrinsically disordered regions (Diebold2023Crystal). Understanding the structure and function of MYCN is essential for developing targeted therapies in oncology.

## Structure
The MYCN protein is a member of the MYC family of proto-oncogenes, characterized by a basic-region/helix-loop-helix/leucine-zipper (bHLHZip) domain. This domain is crucial for protein dimerization and sequence-specific DNA binding, facilitating interactions with the MYC-associated protein X (MAX) to form heterodimers essential for MYC function (RuizPérez2017The). The MYCN protein contains a C-terminal basic region that binds to DNA and a helix-loop-helix leucine zipper domain, which is conserved across the MYC gene family (Wenzel1995The).

The N-terminus of MYCN includes a transcriptional activation domain (TAD) and 'myc-boxes' that are highly conserved and likely involved in transcriptional activity. The myc-box 1 region is significant for transactivation and may interact with the retinoblastoma protein (Rbl) (Wenzel1995The). MYCN is phosphorylated by casein kinase II (CKII), and its stability is regulated by phosphorylation at specific residues, such as Ser-62 and Thr-58, which influence its degradation via the ubiquitin proteasome system (Diebold2023Crystal; RuizPérez2017The).

MYCN is considered 'undruggable' due to its large intrinsically disordered regions, making direct targeting challenging (Diebold2023Crystal). The protein's quaternary structure involves forming heterodimers with MAX, which is crucial for its function (RuizPérez2017The).

## Function
The MYCN proto-oncogene encodes a bHLH transcription factor that plays a critical role in regulating cell proliferation, differentiation, and apoptosis in healthy human cells. MYCN is particularly active in the nucleus, where it forms heterodimers with the MAX protein to bind DNA and regulate the transcription of target genes. This interaction is essential for promoting cell cycle progression, especially the transition from the G1 to the S phase, by upregulating cyclin D2 and influencing other cell cycle regulators such as the CDK inhibitor p27 and E2 factor (E2F) (RuizPérez2017The).

MYCN is involved in the development of the nervous system, with high expression in undifferentiated neural cells and neural stem cells, where it promotes proliferation and maintains pluripotency. It is also crucial for the proliferation of cerebellum progenitor cells and the survival of hematopoietic stem cells (RuizPérez2017The). In the developing lung epithelium, MYCN plays a role in epithelial-mesenchymal interactions and is essential for normal lung development (RuizPérez2017The).

MYCN also regulates metabolic processes, enhancing glycolysis and mitochondrial biogenesis, which supports rapid ATP production and biosynthesis necessary for cell growth (RuizPérez2017The). Its activity is tightly regulated to ensure proper cell cycle control and prevent tumorigenesis (RuizPérez2017The).

## Clinical Significance
The MYCN gene is clinically significant due to its role in various diseases and conditions resulting from mutations, altered expression levels, or disrupted interactions. MYCN amplification is notably associated with aggressive forms of neuroblastoma, a pediatric cancer, where it is present in 25% of all cases and nearly 50% of high-risk cases. This amplification correlates with poor prognosis, rapid tumor growth, and metastasis (Bhavsar2023Metastasis; Braoudaki2021MYCN). In medulloblastoma, MYCN amplification is linked to poor prognosis and is involved in cell cycle progression and apoptosis (RuizPérez2017The). 

MYCN mutations are implicated in Feingold syndrome, an autosomal dominant disorder characterized by digital anomalies and learning disabilities, accounting for 50% of cases (RuizPérez2017The). In prostate cancer, MYCN amplifications are present in 14% of cases and are associated with neuroendocrine differentiation (RuizPérez2017The). MYCN is also involved in basal cell carcinoma, leukemia, and retinoblastoma, where its amplification contributes to tumor initiation and progression (RuizPérez2017The). These findings highlight MYCN as a critical target for therapeutic interventions in oncology.

## Interactions
The MYCN protein, a member of the MYC family of transcription factors, is involved in various protein interactions that influence its role in oncogenesis. MYCN forms heterodimers with the MAX protein through its basic helix-loop-helix leucine zipper (bHLH-Zip) domain, which is crucial for DNA binding and transcriptional regulation. These MYCN/MAX heterodimers activate transcription, while MAX/MAX homodimers typically repress it (Wenzel1991The; Wenzel1995The).

MYCN also interacts with the Polycomb Repressive Complex 2 (PRC2), particularly with components like EZH2, to repress gene expression. This interaction is significant in neuroblastoma, where MYCN recruits PRC2 to the promoter of the tumor suppressor gene CLU, leading to its repression (Corvetta2013Physical).

Additionally, MYCN forms a repression complex with SP1 and MIZ1, recruiting histone deacetylase HDAC1 to the promoters of TRKA and p75NTR genes, thereby repressing their transcription. This complex is important in neuroblastoma malignancy, as it affects the cell's response to nerve growth factor (Iraci2011A).

MYCN also interacts with cofactors such as WDR5 and G9a, which are involved in histone modification. WDR5 acts as a coactivator, while G9a functions as a corepressor, both playing roles in MYCN's regulation of gene transcription (Liu2024MYCN).


## References


[1. (RuizPérez2017The) María Victoria Ruiz-Pérez, Aine Brigette Henley, and Marie Arsenian-Henriksson. The mycn protein in health and disease. Genes, 8(4):113, March 2017. URL: http://dx.doi.org/10.3390/genes8040113, doi:10.3390/genes8040113. This article has 110 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes8040113)

[2. (Bhavsar2023Metastasis) Swapnil Parashram Bhavsar. Metastasis in neuroblastoma: the mycn question. Frontiers in Oncology, May 2023. URL: http://dx.doi.org/10.3389/fonc.2023.1196861, doi:10.3389/fonc.2023.1196861. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2023.1196861)

[3. (Braoudaki2021MYCN) Maria Braoudaki, Kyriaki Hatziagapiou, Apostolos Zaravinos, and George I. Lambrou. Mycn in neuroblastoma: “old wine into new wineskins”. Diseases, 9(4):78, October 2021. URL: http://dx.doi.org/10.3390/diseases9040078, doi:10.3390/diseases9040078. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/diseases9040078)

[4. (Wenzel1995The) A. Wenzel and M. Schwab. The mycn/max protein complex in neuroblastoma. short review. European Journal of Cancer, 31(4):516–519, January 1995. URL: http://dx.doi.org/10.1016/0959-8049(95)00060-v, doi:10.1016/0959-8049(95)00060-v. This article has 38 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/0959-8049(95)00060-v)

[5. (Wenzel1991The) A. Wenzel, C. Cziepluch, U. Hamann, J. Schürmann, and M. Schwab. The n-myc oncoprotein is associated in vivo with the phosphoprotein max(p20/22) in human neuroblastoma cells. The EMBO Journal, 10(12):3703–3712, December 1991. URL: http://dx.doi.org/10.1002/j.1460-2075.1991.tb04938.x, doi:10.1002/j.1460-2075.1991.tb04938.x. This article has 110 citations.](https://doi.org/10.1002/j.1460-2075.1991.tb04938.x)

[6. (Iraci2011A) Nunzio Iraci, Daniel Diolaiti, Antonella Papa, Antonio Porro, Emanuele Valli, Samuele Gherardi, Steffi Herold, Martin Eilers, Roberto Bernardoni, Giuliano Della Valle, and Giovanni Perini. A sp1/miz1/mycn repression complex recruits hdac1 at thetrkaandp75ntrpromoters and affects neuroblastoma malignancy by inhibiting the cell response to ngf. Cancer Research, 71(2):404–412, January 2011. URL: http://dx.doi.org/10.1158/0008-5472.can-10-2627, doi:10.1158/0008-5472.can-10-2627. This article has 78 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.can-10-2627)

[7. (Corvetta2013Physical) Daisy Corvetta, Olesya Chayka, Samuele Gherardi, Cosimo W. D’Acunto, Sandra Cantilena, Emanuele Valli, Izabela Piotrowska, Giovanni Perini, and Arturo Sala. Physical interaction between mycn oncogene and polycomb repressive complex 2 (prc2) in neuroblastoma. Journal of Biological Chemistry, 288(12):8332–8341, March 2013. URL: http://dx.doi.org/10.1074/jbc.M113.454280, doi:10.1074/jbc.m113.454280. This article has 110 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M113.454280)

[8. (Diebold2023Crystal) Mathias Diebold, Lars Schönemann, Martin Eilers, Christoph Sotriffer, and Hermann Schindelin. Crystal structure of a covalently linked aurora-a–mycn complex. Acta Crystallographica Section D Structural Biology, 79(1):1–9, January 2023. URL: http://dx.doi.org/10.1107/s2059798322011433, doi:10.1107/s2059798322011433. This article has 5 citations.](https://doi.org/10.1107/s2059798322011433)

[9. (Liu2024MYCN) Zhihui Liu, Xiyuan Zhang, Man Xu, Jason J. Hong, Amanda Ciardiello, Haiyan Lei, Jack F. Shern, and Carol J. Thiele. Mycn drives oncogenesis by cooperating with the histone methyltransferase g9a and the wdr5 adaptor to orchestrate global gene transcription. PLOS Biology, 22(3):e3002240, March 2024. URL: http://dx.doi.org/10.1371/journal.pbio.3002240, doi:10.1371/journal.pbio.3002240. This article has 1 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1371/journal.pbio.3002240)